EGFR and non-small cell lung carcinoma: Based on the IPASS study (12), a Singaporean study suggested that first-line treatment of EGFR-mutated NSCLC with gefitinib was a cost-effective strategy with a CE estimate of $77,160 Singaporean dollars/QALY (38) compared with carboplatin/paclitaxel, carboplatin/pemetrexed, or carboplatin/pemetrexed/bevacizumab.